[go: up one dir, main page]

IT1253009B - Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini - Google Patents

Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini

Info

Publication number
IT1253009B
IT1253009B ITMI913513A ITMI913513A IT1253009B IT 1253009 B IT1253009 B IT 1253009B IT MI913513 A ITMI913513 A IT MI913513A IT MI913513 A ITMI913513 A IT MI913513A IT 1253009 B IT1253009 B IT 1253009B
Authority
IT
Italy
Prior art keywords
toxin
preparation
ser
arg
vaccines
Prior art date
Application number
ITMI913513A
Other languages
English (en)
Inventor
Wim Hol
Rino Rappuoli
Mario Domenighini
Maria Grazia Pizza
Original Assignee
Sclavo Ricerca S R L
Bioson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11361457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1253009(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sclavo Ricerca S R L, Bioson filed Critical Sclavo Ricerca S R L
Priority to ITMI913513A priority Critical patent/IT1253009B/it
Publication of ITMI913513A0 publication Critical patent/ITMI913513A0/it
Priority to SG1996008033A priority patent/SG48217A1/en
Priority to PT04076971T priority patent/PT1484404E/pt
Priority to DE69233417T priority patent/DE69233417T2/de
Priority to EP04076971A priority patent/EP1484404B1/en
Priority to CA002127091A priority patent/CA2127091C/en
Priority to ES04076971T priority patent/ES2277195T3/es
Priority to DK98200534T priority patent/DK0869181T3/da
Priority to DK93902138T priority patent/DK0620850T3/da
Priority to SG9901947A priority patent/SG93200A1/en
Priority to ES93902138T priority patent/ES2127808T3/es
Priority to ES98200534T priority patent/ES2227762T3/es
Priority to AT98200534T priority patent/ATE277183T1/de
Priority to EP98200534A priority patent/EP0869181B1/en
Priority to EP93902138A priority patent/EP0620850B1/en
Priority to JP51144793A priority patent/JP3394774B2/ja
Priority to AT93902138T priority patent/ATE177145T1/de
Priority to AT04076971T priority patent/ATE346932T1/de
Priority to DE69228563T priority patent/DE69228563T2/de
Priority to AU33476/93A priority patent/AU3347693A/en
Priority to PCT/EP1992/003016 priority patent/WO1993013202A1/en
Priority to DK04076971T priority patent/DK1484404T3/da
Priority to DE69233667T priority patent/DE69233667T2/de
Priority to MYPI92002409A priority patent/MY108154A/en
Priority to MX9207685A priority patent/MX9207685A/es
Priority to TW082100298A priority patent/TW239146B/zh
Priority to SA93130462A priority patent/SA93130462B1/ar
Publication of ITMI913513A1 publication Critical patent/ITMI913513A1/it
Publication of IT1253009B publication Critical patent/IT1253009B/it
Application granted granted Critical
Priority to US08/823,120 priority patent/US6149919A/en
Priority to GR990400555T priority patent/GR3029556T3/el
Priority to US09/819,917 priority patent/US20020044939A1/en
Priority to JP2002119970A priority patent/JP3408529B2/ja
Priority to US10/986,582 priority patent/US7872114B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invenzione si riferisce a tossoidi proteici immunogenici ottenuti per mutagenesi puntiforme del gene di Vibrio Cholerac codificante la Tossina Colerica (CT), o del gene della tossina LT prodotta dai ceppi enterotossigenici di Escherichia coli (ETEC), nei codoni relativi agli aminoacidi Leu-41, Ala-45, Val-53, Ser-63, Ala-72, Ser-75, Val-97, His-107 o Arg-210 singolarmente, o in combinazione con mutazioni a carico dei codoni relativi agli aminoacidi Arg-7, His-44, Arg-54, Ser-61, Glu-110, Glu-112 o Ser-114 ed al loro uso per la preparazione di vaccini utili per il trattamento di infezioni coleriche o diarrea rispettivamente.
ITMI913513A 1991-12-31 1991-12-31 Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini IT1253009B (it)

Priority Applications (32)

Application Number Priority Date Filing Date Title
ITMI913513A IT1253009B (it) 1991-12-31 1991-12-31 Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69233667T DE69233667T2 (de) 1991-12-31 1992-12-30 Immunogene, nichtgiftige Mutanten des Choleratoxins und des Toxins-LT, ihre Herstellung und ihre Verwendung zur Herstellung von Impfstoffen
JP51144793A JP3394774B2 (ja) 1991-12-31 1992-12-30 コレラトキシンの免疫原性無毒化変異体およびトキシンｌｔの免疫原性無毒化変異体，それらの調製，ならびにワクチンの調製のためのそれらの使用
DE69228563T DE69228563T2 (de) 1991-12-31 1992-12-30 Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen
DE69233417T DE69233417T2 (de) 1991-12-31 1992-12-30 Immunogene, nichtgiftige Mutanten des Choleratoxins und des Toxins-LT, ihre Herstellung und ihre Verwendung zur Herstellung von Impfstoffen
EP04076971A EP1484404B1 (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
CA002127091A CA2127091C (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines
ES04076971T ES2277195T3 (es) 1991-12-31 1992-12-30 Mutantes destoxificados inmunogenos de toxina del coleray de la toxina lt, su preparacion y uso en la preparacion de vacunas.
DK98200534T DK0869181T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af LT-tolsin, fremstillingen deraf og anvendelsen deraf til fremstilling af vacciner
DK93902138T DK0620850T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, deres fremstilling og deres anvendelse til fremstil
SG9901947A SG93200A1 (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines
ES93902138T ES2127808T3 (es) 1991-12-31 1992-12-30 Mutantes destoxificados inmunogenos de la toxina del colera y de las toxinas termolabiles (lt), preparacion y utilizacion de los mismos para la preparacion de vacunas.
ES98200534T ES2227762T3 (es) 1991-12-31 1992-12-30 Mutantes destoxificados inmunogenos de toxina del colera y de la toxina lt,su preparacion y uso para la preparacion de vacunas.
AT98200534T ATE277183T1 (de) 1991-12-31 1992-12-30 Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen
EP98200534A EP0869181B1 (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
EP93902138A EP0620850B1 (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines
SG1996008033A SG48217A1 (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin lt their preparation and their use for the preparation of vaccines
AT93902138T ATE177145T1 (de) 1991-12-31 1992-12-30 Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen
AT04076971T ATE346932T1 (de) 1991-12-31 1992-12-30 Immunogene, nichtgiftige mutanten des choleratoxins und des toxins-lt, ihre herstellung und ihre verwendung zur herstellung von impfstoffen
PT04076971T PT1484404E (pt) 1991-12-31 1992-12-30 Mutantes imunogénicos destoxificados da toxina da cólera e das toxinas termolábeis (lt), preparação e utilização destes mutantes para a preparação das vacinas
AU33476/93A AU3347693A (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
PCT/EP1992/003016 WO1993013202A1 (en) 1991-12-31 1992-12-30 Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines
DK04076971T DK1484404T3 (da) 1991-12-31 1992-12-30 Immunogene detoksificerede mutanter af choleratoksin og af toksinet LT, fremstilling deraf og anvendelse deraf til fremstilling af vacciner
MX9207685A MX9207685A (es) 1991-12-31 1992-12-31 Proteina inmunogenica destoxoficada, composicion para vacuna que la contiene y proceso para la formulacion de dicha vacuna.
MYPI92002409A MY108154A (en) 1991-12-31 1992-12-31 Immunogenic detoxified mutants, of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines.
TW082100298A TW239146B (it) 1991-12-31 1993-01-18
SA93130462A SA93130462B1 (ar) 1991-12-31 1993-04-14 طوافر mutants مزالة السمية مولدة للمناعة من سم الكوليرا ومن سم غير ثابت حراريا , تحضيرها واستحدامها لتحضير اللقاحات
US08/823,120 US6149919A (en) 1991-12-31 1997-03-25 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
GR990400555T GR3029556T3 (en) 1991-12-31 1999-03-04 Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines.
US09/819,917 US20020044939A1 (en) 1991-12-31 2001-03-28 Immunogenic detoxified mutants of cholera toxin
JP2002119970A JP3408529B2 (ja) 1991-12-31 2002-04-22 コレラトキシンの免疫原性無毒化変異体およびトキシンｌｔの免疫原性無毒化変異体、それらの調製、ならびにワクチンの調製のためのそれらの使用
US10/986,582 US7872114B2 (en) 1991-12-31 2004-11-12 Immunogenic detoxified mutants of cholera toxin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI913513A IT1253009B (it) 1991-12-31 1991-12-31 Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini

Publications (3)

Publication Number Publication Date
ITMI913513A0 ITMI913513A0 (it) 1991-12-31
ITMI913513A1 ITMI913513A1 (it) 1993-07-01
IT1253009B true IT1253009B (it) 1995-07-10

Family

ID=11361457

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI913513A IT1253009B (it) 1991-12-31 1991-12-31 Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini

Country Status (18)

Country Link
US (1) US6149919A (it)
EP (3) EP1484404B1 (it)
JP (2) JP3394774B2 (it)
AT (3) ATE346932T1 (it)
AU (1) AU3347693A (it)
CA (1) CA2127091C (it)
DE (3) DE69233667T2 (it)
DK (3) DK0620850T3 (it)
ES (3) ES2227762T3 (it)
GR (1) GR3029556T3 (it)
IT (1) IT1253009B (it)
MX (1) MX9207685A (it)
MY (1) MY108154A (it)
PT (1) PT1484404E (it)
SA (1) SA93130462B1 (it)
SG (2) SG48217A1 (it)
TW (1) TW239146B (it)
WO (1) WO1993013202A1 (it)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
DE69434000T3 (de) 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US5981730A (en) * 1994-04-13 1999-11-09 The General Hospital Corporation RPS gene family, primers, probes, and detection methods
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6436407B1 (en) 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
GB9603314D0 (en) * 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
AU6044598A (en) * 1997-01-29 1998-08-18 The Administrators Of The Tulane Eductional Fund Mutant enterotoxin effective as a non-toxic adjuvant for hiv
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP0887403A3 (en) * 1997-06-27 2000-12-06 Chiron S.P.A. Attenuated Vibrio cholerae strains
AU9120898A (en) 1997-08-27 1999-03-16 Chiron Corporation Molecular mimetics of meningococcal b epitopes
WO1999047165A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Production of purified mutant enterotoxin for use as an adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
JP2002518343A (ja) 1998-06-19 2002-06-25 メリウクス オラバクス ヘリコバクター感染に対する非経口的免疫処置法におけるｌｔおよびｃｔ
DE19851282A1 (de) * 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
JP2002533068A (ja) * 1998-12-22 2002-10-08 ボイス トンプソン インスティテュート フォア プラント リサーチ トランスジェニック植物に発現される経口で免疫原性の細菌エンテロトキシン
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ES2350306T3 (es) 1999-02-26 2011-01-20 Novartis Vaccines And Diagnostics, Inc. Uso de bioadhesivos y adyuvantes para la administración de antígenos por vía mucosa.
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
WO2001019998A1 (en) * 1999-09-15 2001-03-22 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
DE60037200T2 (de) * 1999-09-21 2008-09-25 Rutgers, The State University Of New Jersey Orts-spezifisches rekombinationssystem zur manipulation des plastidengenoms in höheren pflanzen
US7186560B2 (en) * 1999-09-21 2007-03-06 Rutgers, The State University Of New Jersey High level expression of immunogenic proteins in the plastids of higher plants
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU2471201A (en) 1999-10-26 2001-06-06 Chiron Corporation Plant lectins as mucosal adjuvants
US20020142006A1 (en) * 2000-03-17 2002-10-03 Mcghee Jerry R. Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
AU2001271268A1 (en) * 2000-05-19 2001-12-03 The Administrators Of The Tulane Educational Fund Hybrid lt-a/ct-b holotoxin for use as an adjuvant
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
ATE499948T1 (de) * 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
CA2437899C (en) 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
AU2002252378B2 (en) 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
US7534936B2 (en) * 2001-03-29 2009-05-19 Rutgers, The State University Of New Jersey Transgenic plants having transformed plastid genomes and progeny thereof
DK1402075T3 (da) 2001-05-22 2013-02-11 Us Gov Nat Inst Health Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
EP1404368B1 (en) * 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CA2449670A1 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
JP4302513B2 (ja) 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003010194A2 (en) 2001-07-27 2003-02-06 Chiron Srl. Meningococcus adhesins nada, app and orf 40
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
NZ535754A (en) 2002-03-15 2007-01-26 Wyeth Corp Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
ATE545651T1 (de) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic Vektoren zur expression von hml-2-polypeptiden
CA2491568A1 (en) * 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
WO2004030631A2 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2003278496A1 (en) * 2002-11-14 2004-06-03 Pfizer Products Inc. Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US6743002B1 (en) * 2003-02-03 2004-06-01 Eaton Corporation Rotary fluid pressure device and improved integral brake assembly
WO2004073603A2 (en) * 2003-02-14 2004-09-02 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
CA2517856A1 (en) * 2003-03-03 2004-09-16 Rutgers, The State University Of New Jersey Removal of plastid sequences by transiently expressed site-specific recombinases
CA2519511A1 (en) * 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0313242D0 (en) * 2003-06-09 2003-07-16 Imp College Innovations Ltd Pulmonary immunopathology
AU2004268375B2 (en) 2003-09-02 2010-01-28 Glaxosmithkline Biologicals S.A. Vaccine
EP2266602A3 (en) 2004-11-01 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
WO2007121467A2 (en) * 2006-04-18 2007-10-25 Rutgers, The State University Of New Jersey Compositions and methods for increasing transgene expression in the plastids of higher plants
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8926993B2 (en) 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9023363B2 (en) * 2008-10-21 2015-05-05 International Vaccine Institute A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
WO2010104883A1 (en) 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
ES2566646T3 (es) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
SG177310A1 (en) 2009-06-22 2012-02-28 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
US9161974B2 (en) 2010-05-23 2015-10-20 Aduro Biotech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
AU2011346535B2 (en) 2010-12-22 2015-09-24 Wyeth Llc Stable immunogenic compositions of Staphylococcus aureus antigens
EP2701734B1 (en) 2011-04-26 2019-09-25 Molecular Express, Inc. Liposomal formulations
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
BR112014011560A2 (pt) 2011-11-14 2017-05-09 Novartis Ag complexos imunogênicos de carbômeros polianiônicos e polipeptídeos env, e métodos de fabricação e uso dos mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
KR101819803B1 (ko) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 혈소판 표적화 치료
HUE060718T2 (hu) 2012-12-20 2023-04-28 Pfizer Glikokonjugációs eljárás
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
EP3068426B1 (en) 2013-11-13 2020-02-12 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
ES2702325T3 (es) 2014-03-11 2019-02-28 Univ Minnesota Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3268034A4 (en) 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016179034A2 (en) 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
KR102045663B1 (ko) 2015-05-04 2019-11-15 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
CN108348593B (zh) 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
EP4659813A2 (en) 2016-03-14 2025-12-10 Universitetet I Oslo Engineered immunoglobulins with altered fcrn binding
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2018183666A1 (en) 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
AU2021332183B2 (en) 2020-08-26 2025-12-18 Pfizer Inc. Group B streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022207793A1 (en) 2021-03-31 2022-10-06 Vib Vzw Vaccine compositions for trypanosomatids
CN113788893B (zh) * 2021-08-11 2022-08-09 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种快速富集霍乱弧菌的偶联特异性单克隆抗体的免疫磁珠及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8333131D0 (en) * 1983-12-12 1984-01-18 Glaxo Group Ltd Microbiological process
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs

Also Published As

Publication number Publication date
PT1484404E (pt) 2007-03-30
EP0869181B1 (en) 2004-09-22
DE69233667T2 (de) 2007-09-27
ES2277195T3 (es) 2007-07-01
TW239146B (it) 1995-01-21
EP0620850A1 (en) 1994-10-26
AU3347693A (en) 1993-07-28
DE69233667D1 (de) 2007-01-11
EP1484404A1 (en) 2004-12-08
DE69233417T2 (de) 2005-09-29
MX9207685A (es) 1994-05-31
DE69228563T2 (de) 1999-07-29
JP3394774B2 (ja) 2003-04-07
EP0620850B1 (en) 1999-03-03
EP0869181A1 (en) 1998-10-07
DK1484404T3 (da) 2007-03-19
ATE177145T1 (de) 1999-03-15
SG93200A1 (en) 2002-12-17
JP3408529B2 (ja) 2003-05-19
DE69233417D1 (de) 2004-10-28
ATE277183T1 (de) 2004-10-15
ATE346932T1 (de) 2006-12-15
CA2127091C (en) 2000-08-01
ITMI913513A0 (it) 1991-12-31
EP1484404B1 (en) 2006-11-29
ES2127808T3 (es) 1999-05-01
DK0620850T3 (da) 1999-09-27
DE69228563D1 (de) 1999-04-08
ES2227762T3 (es) 2005-04-01
SA93130462B1 (ar) 2004-09-01
CA2127091A1 (en) 1993-07-08
SG48217A1 (en) 1998-04-17
DK0869181T3 (da) 2005-01-31
WO1993013202A1 (en) 1993-07-08
US6149919A (en) 2000-11-21
GR3029556T3 (en) 1999-06-30
JPH07506240A (ja) 1995-07-13
ITMI913513A1 (it) 1993-07-01
JP2003000287A (ja) 2003-01-07
MY108154A (en) 1996-08-30

Similar Documents

Publication Publication Date Title
IT1253009B (it) Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69331733T2 (de) Rekombinantes vielwertiges m-protein-vakzin
US20020176863A1 (en) Antigen of hybrid M protein and carrier for group A streptococcal vaccine
IL71652A0 (en) Non-toxinogenic vibrio cholerae mutants
GB9622660D0 (en) Immunogenic detoxified mutant toxin
CA2022420A1 (en) Escherichia coli vaccine
CA2131729A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
IL68790A (en) Polydeoxyribonucleotide coding for ifn-alpha2(arg),plasmid containing it,cloning of said plasmid and microorganisms containing it and ifn-alpha(arg)encoded by said polydeoxyribonucleotide and its preparation
ATE167061T1 (de) Kreuzschützende salmonella impfstoffe
EP0541692A4 (en) Herpes simplex virus vp16 vaccines
TW275632B (it)
ATE98693T1 (de) Derivate des basischen mensch-/rinderfibroblastwachstumsfaktors.
ATE112320T1 (de) Sekretormutante von escherichia coli.
BR9807927A (pt) Uso de uma leishmania mutante na preparação de uma vacina, formulação de vacina, processo de vacinação contra leishmania, uso de uma leishmania mutante na preparacão de uma vacina para a profilaxia e/ou o tratamento de leishmaniose, e, formulação farmacêutica
EP0028172A3 (en) Anticolibacillary animal vaccine, preparation, application and used escherichia coli strains
RU2126447C1 (ru) Способ получения аттенуированного штамма бактерий salmonella и вакцина
ES2137544T3 (es) Procedimiento para la preparacion de un preparado biologico terapeutico sin riesgo de infeccion por virus.
Yao et al. Study on plasmid coding for enterotoxin: 5. Comparison of plasmids from CFA super (+) & CFA-ETEC strains.
MXPA00009490A (en) Use of active p40 conjugates for nasal delivery
RU2001132095A (ru) Штамм бактерий Escherichia coli N 27 0138 К88, используемый для изготовления вакцин и диагностических препаратов
RU94018276A (ru) Штамм бактерий l.monocytogenes усхи-52, используемый для изготовления листериозной вакцины

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971223